Sharemaestro Newsreel

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Rein Therapeutics announced its financial results for the second quarter ended June 30, 2026, highlighting significant progress in its global Phase 2 RENEW trial for LTI-03 in idiopathic pulmonary fibrosis (IPF), having surpassed 25% enrollment and being on track for interim data in H2 …

Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Recommendation of "Hold" by Brokerages

Rein Therapeutics Inc. (NASDAQ:RNTX) has received a consensus "Hold" rating from four brokerages, with an average 12-month price target of $6.00. Institutional investors hold a significant 90.89% stake in the company, with several firms recently increasing their positions. The company reported a narrower-than-expected quarterly …

REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research

Zacks Research has upgraded REGENXBIO (NASDAQ:RGNX) from a "strong sell" to a "hold" rating. This upgrade comes as the biotechnology company exceeded revenue and EPS estimates in its latest quarterly report, though it remains unprofitable. Institutional investors hold a significant portion of the company's …

Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock

Lynx1 Capital Management LP, a 10% owner of Korro Bio (NASDAQ:KRRO), purchased $78,809 worth of common stock in two transactions in early August 2026. These purchases were made at weighted average prices between $11.3998 and $13.1869 per share. The stock has seen significant year-to-date …

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics has initiated its potentially registrational Phase 2 RECLAIM-LN clinical trial for FT819, an off-the-shelf CAR T-cell therapy, to treat refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis. The first patient has been dosed in an outpatient setting, and the study aims …

Fate Therapeutics' First FT819 Patient Went Home Same Day

Fate Therapeutics has initiated its RECLAIM-LN Phase 2 clinical trial for FT819, an off-the-shelf CAR T-cell therapy, in patients with lupus nephritis. The first patient was dosed in an outpatient setting and discharged the same day, with the study aiming to enroll approximately 53 …

Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G

Polar Capital Holdings Plc and Polar Capital LLP have disclosed a 5.28% ownership stake in Arcutis Biotherapeutics, Inc. (ARQT) through a Schedule 13G filing. The investment firm beneficially owns 6,606,945 shares, with sole voting and dispositive power, based on Arcutis's 125,083,374 outstanding shares as …

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

Adlai Nortye Ltd. announced its unaudited financial results for the first half of 2026, reporting a significant decrease in net loss to US$5.3 million and a rise in revenue to US$13.1 million, primarily from a licensing agreement. The company highlighted operational progress in its …

Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) significantly surpassed revenue and EPS expectations in its second-quarter report. Following these strong results, analysts have upgraded their forecasts for 2026, increasing revenue predictions to US$72.9m and EPS to US$0.32, and raising the price target by 13% to US$17.67. The …

Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research

Zacks Research has upgraded Sarepta Therapeutics (NASDAQ:SRPT) from a "strong sell" to a "hold" rating, contributing to a mixed analyst sentiment that results in an overall "Hold" consensus with a $25.06 price target. The company's shares opened at $18.42, with a market cap of …

Irish Jazz Pharmaceuticals acquires American Actio for $1.32 billion

Irish biopharmaceutical company Jazz Pharmaceuticals plc has announced its acquisition of American Actio Biosciences, Inc. for $1.32 billion. The deal involves an upfront payment of $820 million and an additional $500 million contingent on drug approval and sales milestones. Jazz will gain control of …

Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. significantly reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 96.7% in the second quarter, selling 309,427 shares and retaining 10,573 shares valued at $2.55 million. Despite this, institutional investors and hedge funds collectively own 89.14% of the company, and …

Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position

Bain Capital Life Sciences Opportunities III, L.P. has reported a 9.99% beneficial ownership stake in Cabaletta Bio (CABA), as detailed in a recent SCHEDULE 13G/A filing. This ownership comprises 7,709,188 common shares, a warrant for up to 7,500,000 shares, and a pre-funded warrant for …

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?

Key Points Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report. Wall Street is still bullish on the shares.10 stocks we like better than Ionis Pharmaceuticals › Shares of Ionis Pharmaceuticals(NASDAQ: IONS) …

Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake

Bain Capital Life Sciences Opportunities III, LP has reported a 4.75% ownership stake in Kyverna Therapeutics, Inc. (KYTX) through a Schedule 13G/A SEC filing. The fund holds 2,885,000 shares of common stock, representing a passive investment based on the company's 60,795,212 outstanding shares as …

Fate Therapeutics earnings beat by $0.02, revenue topped estimates

Fate Therapeutics (NASDAQ: FATE) announced second-quarter EPS of $-0.250, surpassing analyst estimates by $0.02, and reported revenue of $2.08 million, exceeding the consensus of $1.29 million. The company's stock has seen significant growth, rising 43.590% in the last three months and 131.190% over the …

Minerva Neurosciences, Inc (NASDAQ:NERV) Given Consensus Recommendation of "Reduce" by Brokerages

Minerva Neurosciences, Inc (NASDAQ:NERV) has received a "Reduce" consensus rating from brokerages, with an average 12-month price target of $10.50. This comes as near-term earnings expectations have significantly deteriorated, with HC Wainwright cutting its fiscal 2026 and 2027 EPS estimates, although it projects profitability …

Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants

Balyasny Asset Management L.P. and its affiliates have reported a beneficial ownership of 9.99% in Minerva Neurosciences, Inc. (NERV). This stake comprises 4,654,212 shares, including 4,257,000 shares held directly by Atlas Private Holdings (Cayman) Ltd. and 397,212 shares exercisable from 13,500 warrants. The warrants …

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating

Bernstein has increased its price target for Regeneron Pharmaceuticals (REGN) to $756 from $753, while maintaining a "Market Perform" rating on the stock. This adjustment reflects a modest change in the analyst's valuation, indicating a continued neutral stance on the company's stock performance. The …

Renaissance Technologies LLC Acquires 107,315 Shares of Q32 Bio Inc. $QTTB

Renaissance Technologies LLC significantly increased its stake in Q32 Bio Inc. by acquiring an additional 107,315 shares in the first quarter, bringing its total to 206,915 shares valued at $1.33 million. This comes as Q32 Bio reported better-than-expected quarterly earnings and several other institutional …

How Investors May Respond To Immunocore (IMCR) Turning First-Half Profit Amid Recent Share Price Pullback

Immunocore Holdings plc reported a significant improvement in its financial performance, achieving profitability in the first half of 2026 with net income of US$12.16 million, up from a loss the previous year. This positive shift is driven by increased revenue, though the company's investment …

Balyasny Asset Management (CLRB) discloses 9.99% Cellectar stake via stock and warrants

Balyasny Asset Management and affiliated entities have disclosed a 9.99% beneficial ownership stake in Cellectar Biosciences (CLRB) through a Schedule 13G SEC filing. This stake comprises 220,000 common shares and 578,382 shares issuable upon the exercise of warrants, all held under a 9.99% Beneficial …

Contineum Therapeutics (CTNM): Balyasny group reports 7.14% stake in 13G/A filing

Balyasny Asset Management and its affiliated entities have reported a 7.14% beneficial ownership stake in Contineum Therapeutics (CTNM) Class A common stock through a Schedule 13G/A filing. This equates to 2,335,550 shares, with sole voting and dispositive power, based on 32,723,877 shares outstanding as …

Valneva SE earnings missed by $0.18, revenue fell short of estimates

Valneva SE reported second-quarter earnings per share of $-0.39, missing analyst estimates by $0.18. The company's revenue for the quarter was $40.29 million, falling short of the consensus estimate of $44.17 million. Valneva SE's stock price has declined by -0.53% in the last 3 …

Innate Pharma prices €30M share offering to fund lead cancer drug

Innate Pharma has priced a €30 million share offering to fund the clinical development of its lead cancer drug candidate, IPH4502, and its preclinical antibody-drug conjugate portfolio. The French biotech issued 17,647,059 new ordinary shares at €1.70 each, expecting net proceeds of €27.6 million. …

Handelsbanken Fonder AB Has $10.38 Million Stock Position in Axsome Therapeutics, Inc. $AXSM

Handelsbanken Fonder AB significantly increased its stake in Axsome Therapeutics, Inc. by 216.4% in the second quarter, now holding 42,400 shares valued at $10.38 million. This comes despite Axsome Therapeutics missing analyst expectations for both earnings and revenue in its latest quarterly report. The …

GH Research PLC (NASDAQ:GHRS) Receives Average Rating of "Moderate Buy" from Analysts

GH Research PLC (NASDAQ:GHRS) has received an average rating of "Moderate Buy" from analysts, with ten out of twelve recommending a buy and an average 12-month price target of $45.00 against a current price of $28.19. Despite beating quarterly earnings estimates, analysts foresee continued …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

Pomerantz LLP is investigating potential securities fraud claims against Immix Biopharma, Inc. (IMMX) following a significant drop in its stock price. The investigation stems from the company's termination of its Chief Medical Officer, Richard Graydon, who was later identified by media outlets as Ronald …

Citizens reiterates Immix Biopharma stock rating on pipeline progress

Citizens reiterated a "Market Outperform" rating and a $23.00 price target for Immix Biopharma (NASDAQ:IMMX), citing strong pipeline progress and potential for significant upside despite recent financial losses and an "overvalued" assessment by InvestingPro. The firm highlighted upcoming top-line results for NXC-201 in September …

Balyasny reports 4.84% Rezolute (RZLT) stake in Schedule 13G/A

Balyasny Asset Management and its affiliated entities have reported a 4.84% beneficial ownership stake in Rezolute, Inc. (RZLT) common stock through a Schedule 13G/A filing. This ownership amounts to 4,662,039 shares held via Atlas Diversified Master Fund, Ltd., representing 4.84% of Rezolute's outstanding shares …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group Inc. (REPL) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Replimune Group Inc. (REPL) after the FDA deemed the company's lead trial for its skin cancer drug RP1 "not interpretable," causing a significant drop in stock price. The firm is encouraging shareholders who purchased Replimune securities to …

Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals

Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A

Sirenia Capital Management LP and Alex Silverstein have reported a 4.3% beneficial ownership stake in Immunome Inc. (IMNM) through an amended Schedule 13G filing. They collectively hold 4,832,279 shares of common stock, representing 4.3% of the 113,250,394 shares outstanding as of May 7, 2026. …

Cyclerion Therapeutics (CYCN): Balyasny group discloses 7.33% equity position

Balyasny Asset Management L.P. and its affiliated entities have disclosed a 7.33% beneficial ownership stake in Cyclerion Therapeutics, Inc. (CYCN). The group holds 317,511 shares of common stock through Atlas Diversified Master Fund, Ltd., exercising sole voting and dispositive power over these shares. This …

Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A

Innate Pharma (IPHA) plans August 14, 2026 conference call and webcast